Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) is set to announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Lexicon Pharmaceuticals Stock Performance
Lexicon Pharmaceuticals stock traded down $0.05 during trading hours on Tuesday, reaching $1.52. 1,337,028 shares of the stock were exchanged, compared to its average volume of 4,277,389. The stock has a market cap of $373.05 million, a P/E ratio of -1.95 and a beta of 1.27. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. Lexicon Pharmaceuticals has a 52-week low of $0.92 and a 52-week high of $3.79. The firm’s 50 day moving average is $2.17 and its 200 day moving average is $1.73.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Recommended Stories
- Five stocks we like better than Lexicon Pharmaceuticals
- What Are Dividend Challengers?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What is a Special Dividend?
- Hilton Demonstrates Asset Light is Right for Investors
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.